TOKYO -- Nippon Kayaku could seek government approval by the end of this fiscal year for a new cancer treatment selectively targeting tissues to deliver drugs in miniscule capsules.
The Japanese drug and chemical maker will request permission from the Ministry of Health to make and sell a new therapy using capsules containing Paclitaxel, a drug often used to treat breast cancer. Clinical trials on around 60 patients here showed that the treatment was more effective and produced fewer side effects than existing therapies. Nippon Kayaku is currently compiling data from the final stages of the trials, and expects to have all the information necessary for the approval process by next spring.
